188 related articles for article (PubMed ID: 31354102)
1. Front-line use of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: Practice considerations.
Reff MJ; Shillingburg A; Shah B; Elder C; Prescott H; Kennerly-Shah J
J Oncol Pharm Pract; 2020 Jan; 26(1):156-174. PubMed ID: 31354102
[TBL] [Abstract][Full Text] [Related]
2. BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Cuellar S; Vozniak M; Rhodes J; Forcello N; Olszta D
J Oncol Pharm Pract; 2018 Sep; 24(6):433-452. PubMed ID: 28580869
[TBL] [Abstract][Full Text] [Related]
3. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia.
Lam MS; Cheung N
J Oncol Pharm Pract; 2016 Dec; 22(6):741-748. PubMed ID: 26419691
[TBL] [Abstract][Full Text] [Related]
4. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
Wong SF; Mirshahidi H
Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.
Carneiro BA; Kaplan JB; Giles FJ
Expert Rev Hematol; 2015 Aug; 8(4):457-79. PubMed ID: 25938861
[TBL] [Abstract][Full Text] [Related]
6. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
7. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
8. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2016 Feb; 91(2):252-65. PubMed ID: 26799612
[TBL] [Abstract][Full Text] [Related]
11. How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.
Perrone S; Massaro F; Alimena G; Breccia M
Expert Opin Pharmacother; 2016 Aug; 17(11):1517-26. PubMed ID: 27231757
[TBL] [Abstract][Full Text] [Related]
12. Impact of risk score calculations in choosing front-line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase.
Hu B; Savani BN
Eur J Haematol; 2014 Sep; 93(3):179-86. PubMed ID: 24766312
[TBL] [Abstract][Full Text] [Related]
13. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
15. Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017.
Khoury HJ; Williams LA; Atallah E; Hehlmann R
Am Soc Clin Oncol Educ Book; 2017; 37():468-479. PubMed ID: 28561719
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia.
Breccia M; Alimena G
Cancer Lett; 2014 May; 347(1):22-8. PubMed ID: 24508029
[TBL] [Abstract][Full Text] [Related]
17. Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors.
Gugliotta G; Castagnetti F; Fogli M; Cavo M; Baccarani M; Rosti G
Expert Rev Hematol; 2013 Oct; 6(5):563-74. PubMed ID: 24083631
[TBL] [Abstract][Full Text] [Related]
18. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
19. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
20. Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia.
Pinilla-Ibarz J; Sweet K; Emole J; Fradley M
Anticancer Res; 2015 Dec; 35(12):6355-64. PubMed ID: 26637844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
